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Despite the best intentions to base medical
practice on evidence, many decisions must
still be made under uncertainty. The
choice of antibiotics for prophylaxis in
cardiac surgery is one of these. Although
there is a consensus that antibiotic pro-
phylaxis is effective, few rigorous studies
have compared the regimens that are most
relevant to current clinical care.
Vancomycin is often used because of
concern about the increasing prevalence
of resistance to cephalosporins in Staph-
ylococcus aureus and coagulase-negative
staphylococci, the pathogens that most
frequently cause surgical site infection
(SSI) after cardiac surgery [1]. The debate
about glycopeptide prophylaxis is lively
because of the concerns that use of these
agents may promote the emergence and
the spread of resistance to this family of
antibiotics among enterococci and staph-
ylococci. The Centers for Disease Control
and Prevention (CDC) recommends that
vancomycin only be used as perioperative
prophylaxis “at institutions that have a
high rate of infections caused by methi-
cillin-resistant S. aureus (MRSA) or meth-
icillin-resistant S. epidermidis” [2, p. 3].
However, the CDC guidelines provide no
guidance about what rate is sufficiently
high to warrant use of vancomycin. The
amount of glycopeptide use at stake is all
the larger as these considerations apply to
many clean surgical procedures other than
cardiac surgery.
In this context, the meta-analysis by Bo-
lon et al. [3] of studies in which prophy-
laxis with glycopeptides is compared with
prophylaxis with b-lactam antibiotics is
welcome. The authors pooled data from
5761 cardiac procedures from 7 random-
ized trials. They found that neither anti-
biotic family was superior for prevention
of SSIs. Of note, however, b-lactam pro-
phylaxis prevented 50% more chest SSIs
than did glycopeptide prophylaxis.
One limitation of the study, as pointed
out by the authors themselves, is that there
was some degree of heterogeneity among
the selected trials. These trials used dif-
ferent antibiotics, different definitions of
SSI, and different protocols for surveil-
lance of SSIs. Nonetheless, the authors
made the best possible use of the available
data and appropriately concluded that
these data do not support a switch from
b-lactams to glycopeptides for prophylaxis
in cardiac surgery. Useful as this analysis
is, some important questions remain.
• Is there a threshold value for preva-
lence of methicillin resistance that
would justify prophylaxis with glyco-
peptides?
In their meta-analysis, Bolon et al. [3]
found that the risk of SSI caused by b-
lactam–resistant (presumably, methicillin-
resistant), gram-positive organisms in pa-
tients who received prophylaxis with
glycopeptides was one-half of that ob-
served for those who received b-lactam
antibiotics. Local prevalence of methicillin
resistance will therefore be a key factor in
the choice of a prophylactic strategy. Un-
fortunately, the meta-analysis does not
help in choosing a threshold above which
glycopeptides should be used for prophy-
laxis, mainly because precise data on
methicillin resistance were not available in
the 7 selected studies. Two of these studies
were published 110 years ago and are un-
likely to reflect the current prevalence of
bacteriological resistance. Only the most
recent study [4], which was conducted in
Israel during 1997–1999, described a high
prevalence of MRSA in its source popu-
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lation, although this prevalence was not
precisely specified. Of note, no advantage
of vancomycin prophylaxis was found
overall, even in this study.
• Do glycopeptides and b-lactams have
similar activity against methicillin-
susceptible, gram-positive cocci?
If glycopeptides are to be used because
of their advantage against methicillin-
resistant pathogens, one must be sure that
this advantage is not counterbalanced by
a weaker effect in preventing SSI caused
by methicillin-susceptible bacteria. Several
lines of evidence suggest weaker activity
of glycopeptides. Pharmacokinetic and
pharmacodynamic studies have shown
poor tissue penetration and slow bacterial
killing [5, 6]. b-Lactams were repeatedly
shown to be more effective than glyco-
peptides in animal models of endocarditis
caused by methicillin-susceptible, gram-
positive bacteria [7, 8]. Bolon et al. [3]
conducted subgroup analyses that sug-
gested a clinical counterpart of these ex-
perimental findings: in the pooled popu-
lation, patients who received prophylaxis
with a glycopeptide developed signifi-
cantly more chest infections than did those
who received b-lactams; they also had a
nonsignificant trend towards a higher risk
of deep-chest infection. However, there is
not enough information to know whether
the excess was due to methicillin-suscep-
tible, gram-positive cocci or to other b-
lactam–susceptible pathogens. In addi-
tion, the contradictory finding of a trend
towards smaller risk of leg infection for
glycopeptide recipients reminds us that
the results of these subgroup analyses may
be due to chance rather than to a differ-
ence in preventive efficacy between the 2
prophylactic strategies.
• What is the real impact of glycopep-
tide use on the epidemiology of re-
sistance to glycopeptides?
The potential for promoting the emer-
gence of resistance by using glycopeptides
is obvious. Most of the patients who were
reported to be infected with glycopeptide-
resistant or glycopeptide-intermediate S.
aureus had previously received prolonged
courses of vancomycin for infections
caused by MRSA [9, 10]. However, epi-
demiological data are still lacking to trans-
late this paradigm into broader clinical
practice. For instance, vancomycin has
been less consistently reported to be a risk
factor for infections caused by vancomy-
cin-resistant enterococci, compared with
cephalosporins [11]. In addition, short ex-
posures to glycopeptides for prophylaxis
in patients with non-MRSA infections are
far less likely to promote resistance than
are prolonged treatments, especially for
MRSA infections. Additional data are war-
ranted in this context—for instance, data
obtained using time-series analyses to
compare the impact of different strategies
regarding use of glycopeptides on resis-
tance [12].
We recently developed a decision-ana-
lytic model to calculate the clinical benefits
and costs associated with the use of either
cefazolin or vancomycin for prophylaxis
in coronary artery bypass surgery [13]. In
the base case, in which 40% of S. aureus
isolates and 80% of coagulase-negative
staphylococci were resistant to methicillin,
cefazolin had to be 25% better than van-
comycin against susceptible organisms to
be more effective. A performance advan-
tage for cefazolin against drug-susceptible
organisms was required unless the prev-
alence of methicillin resistance was !3%.
This example illustrates the uncertainty
around the effects of vancomycin pro-
phylaxis: choosing cefazolin over vanco-
mycin for cardiac surgery may be detri-
mental to the individual patient in many
hospitals.
The analysis of Bolon et al. [3] allows
us to conclude that there is no empirical
evidence supporting a switch from b-lac-
tams to glycopeptides for routine prophy-
laxis for cardiac surgery. However, we con-
tinue to make decisions under uncertainty,
not knowing with assurance to which en-
vironments their analysis applies. We look
forward to new data and updated analyses
to help clinicians make the best choice
based on the most common and serious
pathogens at each institution.
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